1. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg. 2007;104 (3):575-81. [DOI via Crossref] [Pubmed] | | 2. de Kam PJ, van Kuijk J, Prohn M, Thomsen T, Peeters P. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study. Clin Drug Investig. 2010;30 (9):599-611. [DOI via Crossref] [Pubmed] | | 3. Tokuwaka J, Takahashi S, Tanaka M. Anaphylaxis after sugammadex administration. Can J Anaesth. 2013;60 (7):733-4. [DOI via Crossref] [Pubmed] | | 4. Ohshita N, Tsutsumi YM, Kasai A, Soga T, Kanamura T, Katayama T, et al. Two cases of anaphylactoid reaction after administration of sugammadex. [Article in Japanese]. Masui. 2012;61(11):1261-4. [Pubmed] | | 5. Osaka Y, Shimada N, Satou M, Masuda T, Ando T, Kozono Y, et al. A case of atrioventricular block (Wenckebach type) induced by sugammadex. JAnesth. 2012;26 (4):627-8. [DOI via Crossref] [Pubmed] | | 6. Butterworth JF, Mackey DC, Wasnick JD, Morgan GE,Mikhail MS. Morgan & Mikhail's clinical anesthesiology. 5thed. New York: McGraw-Hill Medical Publishing. 2013. | | 7. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg. 2007;104 (3):569-74. [DOI via Crossref] [Pubmed] | | 8. Booij LH, van Egmond J, Driessen JJ, de Boer HD. In vivo animal studies with sugammadex. Anaesthesia. 2009;64 (1):38-44. [DOI via Crossref] [Pubmed] | | 9. Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth. 2006;96 (1):36-43. [DOI via Crossref] [Pubmed] | | 10. Kokki M, Ali M, Turunen M, Kokki H. Suspected unexpected adverse effect of sugammadex: hypotension. Eur J Clin Pharmacol. 2012;68 (5):899-900. [DOI via Crossref] [Pubmed] | | 11. de Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology. 2007;107(2):239-44. [DOI via Crossref] [Pubmed] | | 12. Puhringer FK, Rex C, Sielenkamper AW, Claudius C, Larsen PB, Prins ME, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology. 2008;109(2):188-97. [DOI via Crossref] [Pubmed] | | 13. Groudine SB, Soto R, Lien C, Drover D, Roberts K. A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg. 2007;104(3):555-62. [DOI via Crossref] [Pubmed] | |
|
|